AIDS (London, England) · 2025
Incidence of metabolic syndrome in people with HIV who start dolutegravir based-regimen compared with bictegravir based-regimen after 48 weeks.
СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mata Marín José Antonio, Rodríguez Evaristo Mara Soraya, Cano Díaz Ana Luz, Salinas Velázquez Gloria Elizabeth, Triana González Salma, Chaparro Sánchez Alberto, Pompa Mera Ericka, Meneses Cisneros Betzahida, Gaytán Martínez Jesús Enrique, MICTLAN study group
Аннотация
OBJECTIVE: Evidence suggests that patients initiating a second-generation integrase strand transfer inhibitors (INSTI)-based regimen may have a higher risk of developing metabolic syndrome (MetS) compared to those on other antiretroviral classes. This study aimed to describe the incidence of MetS at 48 weeks, based on ATP III criteria, in people with HIV (PWH) who started antiretroviral therapy (ART) with a DTG/ABC/3TC-based regimen compared to those receiving a BIC/TAF/FTC-based regimen.
DESIGN: A randomized, open-label clinical trial was conducted in PWH with no prior exposure to ART.
METHODS: Participants were randomized to receive either bictegravir/alafenamide tenofovir/emtricitabine (BIC/TAF/FTC) or dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). Anthropometric measurements, including weight, height, blood pressure, waist circumference, bioelectrical impedance analysis, and visceral fat assessment via ultrasonography, were performed at baseline, 24 weeks, and 48 weeks. Metabolic parameters were evaluated at each visit.
RESULTS: Out of 378 subjects, 311 provided informed consent and were included. Of these, 276 completed 48 weeks of follow-up. The incidence of MetS was 6 (3.9%) and 10 (6.3%) in BIC/TAF/FTC and DTG/ABC/3TC arms, respectively, with no significant difference between groups. In the BIC/TAF/FTC group, 24 patients (9%) experienced a weight gain of ≥10%, compared to 16 patients (6%) in the DTG/ABC/3TC group ( P = 0.72). Risk factors for MetS were age ≥40 years old, baseline BMI ≥25 kg/m 2 , and baseline visceral fat ≥5 cm prior to ART initiation.
CONCLUSION: Incidence of MetS among PWH receiving an INSTI-based regimen was high, with no difference between BIC/TAF/FTC and DTG/ABC/3TC groups. Age, overweight and elevated visceral fat at baseline were all associated with MetS.
DESIGN: A randomized, open-label clinical trial was conducted in PWH with no prior exposure to ART.
METHODS: Participants were randomized to receive either bictegravir/alafenamide tenofovir/emtricitabine (BIC/TAF/FTC) or dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). Anthropometric measurements, including weight, height, blood pressure, waist circumference, bioelectrical impedance analysis, and visceral fat assessment via ultrasonography, were performed at baseline, 24 weeks, and 48 weeks. Metabolic parameters were evaluated at each visit.
RESULTS: Out of 378 subjects, 311 provided informed consent and were included. Of these, 276 completed 48 weeks of follow-up. The incidence of MetS was 6 (3.9%) and 10 (6.3%) in BIC/TAF/FTC and DTG/ABC/3TC arms, respectively, with no significant difference between groups. In the BIC/TAF/FTC group, 24 patients (9%) experienced a weight gain of ≥10%, compared to 16 patients (6%) in the DTG/ABC/3TC group ( P = 0.72). Risk factors for MetS were age ≥40 years old, baseline BMI ≥25 kg/m 2 , and baseline visceral fat ≥5 cm prior to ART initiation.
CONCLUSION: Incidence of MetS among PWH receiving an INSTI-based regimen was high, with no difference between BIC/TAF/FTC and DTG/ABC/3TC groups. Age, overweight and elevated visceral fat at baseline were all associated with MetS.